Analysis of absorbed dose in radioimmunotherapy with 177Lu-trastuzumab using two different imaging scenarios: a pilot study

Author:

Nautiyal Amit,Jha Ashish K.,Mithun Sneha,Shetye Bhakti,Kameswaran Mythili,Shah Sneha,Rangarajan Venkatesh,Gupta Sudeep

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference49 articles.

1. Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer.;James;Indian J Med Res,2011

2. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.;Ross;Oncologist,2003

3. Radiolabelled monoclonal antibodies in the treatment of metastatic cancer.;Goldenberg;Curr Oncol,2007

4. HER-2-positive metastatic breast cancer: trastuzumab and beyond.;Metro;Expert Opin Pharmacother,2008

5. 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer.;Rasaneh;Nucl Med Biol,2010

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review;Clinical and Translational Imaging;2023-09-20

2. The current role of nuclear medicine in breast cancer;The British Journal of Radiology;2023-09

3. PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer;Journal of Clinical Medicine;2023-07-25

4. Theranostic Imaging and Radiopharmaceutical Therapy;Radiopharmaceutical Therapy;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3